Exercise and the Prevention of Heart Failure in Breast Cancer Patients.

Not Applicable

Completed

• Conditions: Breast Cancer; Heart Failure; Anthracycline based chemotherapy regimen; Cancer - Breast; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12616001602415
• Lead Sponsor: Baker IDI Heart and Diabetes Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Diagnosed with Breast Cancer
Scheduled for Anthracycline-based chemotherapy.
Capable of walking up two flights of stairs

Exclusion Criteria

Sustained irregular heartbeat (eg atrial fibrillation).
Contraindication to Cardiac MRI such as implanted metallic device (eg pacemaker).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiac function (ejection fraction) during exercise magnetic resonance.[At baseline and 3 weeks after the last cycle of anthracycline chemotherapy]

Secondary Outcome Measures

Name	Time	Method
Peak VO2 = Oxygen uptake measured at maximum exercise. This will be assessed with a cardiopulmonary exercise test on an upright cycle ergometer.[At baseline and 3 weeks after the last cycle of anthracycline chemotherapy];Adherence to exercise as % of planned days completed.<br>The accredited exercise physiologist completes clinical notes after each session and the participant keeps an exercise diary.. Each participant will complete a total of 24 sessions (supervised by an accredited exercise physiologist) and 12 unsupervised sessions).[Throughout the exercise intervention from baseline to follow-up.];Echocardiographic assessment of Left Ventricular Systolic function (ejection fraction).[At baseline and 3 weeks after the last cycle of anthracycline chemotherapy.]